Your session is about to expire
← Back to Search
MT-1186 for Lou Gehrig's Disease
Study Summary
This trial is comparing two dosing regimens of oral edaravone to see which is more effective in treating ALS. The primary outcome measure is time from randomization to either a 12-point decrease in ALSFRS-R score or death, whichever happens first.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 185 Patients • NCT04165824Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: MT-1186 - Group 1
- Group 2: MT-1186 - Group 2
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the previous studies that have been done on MT-1186?
"Right now, there are 9 ongoing studies involving MT-1186 with 3 of them in Phase 3. Most research on MT-1186 is taking place in Shanghai but 188 total locations are running clinical trials for this medication."
Is MT-1186 a health hazard for human beings?
"We believe that MT-1186 is relatively safe, as it has received a score of 3. This means that it is a Phase 3 trial, for which there is some data supporting efficacy and multiple rounds of safety data."
Are we currently enrolling patients for this trial?
"From what is available on clinicaltrials.gov, it seems as though this study is still looking for patients to participate. The listing was put up on 1/11/2022 and the most recent update was on 11/11/2022."
How many people are being included in this experiment?
"Based on the information available from clinicaltrials.gov, this clinical trial is still recruiting patients. The study was first posted on January 11th, 2022 and was last updated November 11th of the same year. They are looking for a total of 300 patients to be spread out over 16 locations."
Is this a groundbreaking clinical trial?
"At present, there are 9 active studies for MT-1186 underway in 98 cities and 10 countries. The first study for MT-1186 was conducted in 2020 by Mitsubishi Tanabe Pharma Development America, Inc. This initial Phase 3 drug approval stage study involved 140 participants and completed successfully. Since 2020, a total of 18311 studies have been completed related to MT-1186."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Most responsive sites:
- Nerve And Muscle Center Of Texas: < 48 hours
Share this study with friends
Copy Link
Messenger